A double whammy for Syndex Bio molecular technologies has seen an oversubscribed $15.5million seed financing round closed, ...

Princeton seniors Katie Daniels ’26 and Braeden Carroll ’26 awarded the University’s highest undergraduate honor, the Moses Taylor Pyne Prize, in recognition of their exceptional scholarship, ...

Syndex Bio, a biotechnology company advancing next‑generation molecular diagnostics, today announced the introduction of its proprietary mcPCR ™ (methyl‑copying PCR) platform at the Advances in Genome ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 3 of Bionano Symposium 2026, entitled OGM Making its Mark in Constitutional Genetic Disorders. Presentations highlighted how ...

Researchers from New England Biolabs and Yale University have created a system for engineering the first fully synthetic bacteriophages that could help with future clinical development of phage ...

Several years worth of findings from a floating laboratory have tapped into a well-stocked coral library of taxonomic, ...

Brain freeze — the sharp, seconds-long headache we get from ingesting something cold — is rooted in the way our brain senses ...

Science is a subject built on doing. Students learn chemistry through titrations, biology through dissections, physics through motion experiments, and earth science through field observations. That ...

Bionano Symposium 2026 continues with Day 2: New Frontiers in Oncology and Bioprocessing Applications on February 24, 2026, from 7:00-10:00 AM PT. Attendees may also explore scientific posters ...

Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from the fourth and final day of Symposium 2026. Day 4 featured updates from some of the most advanced and high-volume cytogenetics and ...

ERS Genomics Limited ('ERS'), the CRISPR licensing company, today announced the launch of its Early Access Express License, a new licensing option designed to support early stage innovators at ...

The FDA has sketched out its new regulatory pathway to market for individualised therapies that treat ultra-rare diseases, based on a 'plausible mechanism' premise.